CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Similarly, Zepbound is Mounjaro’s weight-loss counterpart ... said many of his patients report life-changing weight loss while on GLP-1 medications. “I have some veterans who have lost ...